Eye implant triggers sight improvements in GA at 36 months, pivotal study finds
These results come as the FDA currently mulls PRIMA’s fate on the US ophthalmic device market.
These results come as the FDA currently mulls PRIMA’s fate on the US ophthalmic device market.
Surging demand for injectable therapies (led by GLP‑1s) is exposing a new constraint in drug delivery: not innovation, but the ability to industrialise and manufacture devices at scale.
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
Australia starts investigation into OpenAI Medicare breach
Industry partnership will determine the success of the transition to low-GWP pMDIs
UK government champions healthtech through new NHS access programme
Intuitive Surgical expands platforms despite market headwind